Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension of KRN23 in Adults with XLH
NCT02312687Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Jan 2015
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of burosumab in X-linked hypophosphatemia (XLH), sponsored by Kyowa Kirin. Primary endpoints: Number of Participants With Adverse Events, Percentage of Participants Reaching Serum Phosphorus Normal Range and 6 more. Started Jan 2015; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphatemia (XLH)
Beyond the preview
Go deeper on NCT02312687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02312687.